Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
David Bernstein,1 Rakesh Tripathi,2 Daniel E Cohen2 1Zucker School of Medicine, Hofstra University, Hempstead, New York, NY, USA; 2AbbVie Inc., North Chicago, IL, USA Background: This international, phase 2, open-label, multicenter study (ClinicalTrials.gov Identifier: NCT01609933) was conducted to...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2019
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/c3bb15136c2543d7be125f6855018503 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|